Eric Clambey
Concepts (413)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gammaherpesvirinae | 8 | 2021 | 45 | 1.960 |
Why?
| | Herpesviridae Infections | 6 | 2021 | 148 | 1.450 |
Why?
| | CD8-Positive T-Lymphocytes | 13 | 2021 | 928 | 1.330 |
Why?
| | Gene Expression Regulation, Viral | 5 | 2021 | 100 | 1.180 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 2021 | 395 | 1.080 |
Why?
| | B7-H1 Antigen | 5 | 2024 | 233 | 0.870 |
Why?
| | Receptor, Adenosine A2B | 4 | 2013 | 65 | 0.770 |
Why?
| | Immunologic Memory | 8 | 2020 | 365 | 0.730 |
Why?
| | Head and Neck Neoplasms | 7 | 2022 | 562 | 0.720 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2020 | 367 | 0.700 |
Why?
| | Virus Replication | 4 | 2021 | 544 | 0.690 |
Why?
| | RNA, Untranslated | 3 | 2021 | 124 | 0.680 |
Why?
| | Virus Latency | 6 | 2021 | 80 | 0.670 |
Why?
| | Mice | 44 | 2024 | 18378 | 0.670 |
Why?
| | Host-Pathogen Interactions | 3 | 2019 | 369 | 0.660 |
Why?
| | Flow Cytometry | 5 | 2018 | 1192 | 0.640 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2580 | 0.620 |
Why?
| | Virus Activation | 5 | 2021 | 86 | 0.610 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 177 | 0.600 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1487 | 0.600 |
Why?
| | Animals | 56 | 2024 | 38010 | 0.590 |
Why?
| | Immunomodulation | 2 | 2019 | 102 | 0.590 |
Why?
| | Ischemia | 4 | 2015 | 416 | 0.590 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2020 | 302 | 0.570 |
Why?
| | Clone Cells | 3 | 2008 | 270 | 0.530 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 686 | 0.530 |
Why?
| | Interleukin-10 | 1 | 2019 | 311 | 0.510 |
Why?
| | Tumor Microenvironment | 9 | 2021 | 732 | 0.510 |
Why?
| | Mice, Inbred C57BL | 24 | 2023 | 6043 | 0.500 |
Why?
| | Ikaros Transcription Factor | 2 | 2013 | 25 | 0.480 |
Why?
| | G(M1) Ganglioside | 1 | 2015 | 7 | 0.470 |
Why?
| | Kidney Diseases | 2 | 2020 | 412 | 0.470 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2021 | 80 | 0.470 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 335 | 0.460 |
Why?
| | Hypoxia | 2 | 2013 | 1177 | 0.450 |
Why?
| | RNA, Viral | 1 | 2019 | 704 | 0.450 |
Why?
| | T-Lymphocytes | 4 | 2017 | 2026 | 0.450 |
Why?
| | Diagnostic Imaging | 1 | 2018 | 333 | 0.440 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2024 | 875 | 0.440 |
Why?
| | Mice, Transgenic | 10 | 2019 | 2194 | 0.430 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 475 | 0.420 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2021 | 194 | 0.420 |
Why?
| | Mice, Knockout | 11 | 2023 | 3109 | 0.410 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2023 | 272 | 0.410 |
Why?
| | Antibodies | 1 | 2015 | 402 | 0.400 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 772 | 0.390 |
Why?
| | Forkhead Transcription Factors | 2 | 2019 | 203 | 0.390 |
Why?
| | RNA, Messenger | 2 | 2019 | 2852 | 0.380 |
Why?
| | Interleukin-12 | 1 | 2013 | 124 | 0.370 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2020 | 1226 | 0.370 |
Why?
| | Cisplatin | 2 | 2024 | 333 | 0.370 |
Why?
| | Aging | 5 | 2018 | 1946 | 0.370 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2020 | 1130 | 0.350 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2012 | 296 | 0.350 |
Why?
| | Gene Expression Regulation | 4 | 2015 | 2621 | 0.340 |
Why?
| | Immunotherapy | 4 | 2021 | 659 | 0.340 |
Why?
| | Endotoxins | 1 | 2012 | 213 | 0.340 |
Why?
| | Kidney | 5 | 2023 | 1507 | 0.340 |
Why?
| | Neutrophils | 2 | 2017 | 1134 | 0.340 |
Why?
| | Radioimmunotherapy | 2 | 2021 | 21 | 0.340 |
Why?
| | Radiation Tolerance | 3 | 2021 | 104 | 0.330 |
Why?
| | Pneumonia | 3 | 2017 | 647 | 0.310 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2020 | 263 | 0.310 |
Why?
| | Cyclins | 2 | 2021 | 101 | 0.290 |
Why?
| | Mice, Inbred BALB C | 8 | 2021 | 1272 | 0.290 |
Why?
| | STAT3 Transcription Factor | 2 | 2020 | 211 | 0.280 |
Why?
| | Open Reading Frames | 2 | 2018 | 133 | 0.280 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1133 | 0.280 |
Why?
| | Interferon-gamma | 3 | 2020 | 791 | 0.270 |
Why?
| | Acute Kidney Injury | 2 | 2012 | 831 | 0.270 |
Why?
| | Signal Transduction | 6 | 2019 | 5214 | 0.270 |
Why?
| | Oxygen | 1 | 2013 | 998 | 0.270 |
Why?
| | Immunophenotyping | 2 | 2019 | 326 | 0.260 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2018 | 16 | 0.260 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 664 | 0.250 |
Why?
| | Viral Proteins | 4 | 2021 | 370 | 0.250 |
Why?
| | Inflammation | 4 | 2020 | 2881 | 0.240 |
Why?
| | Nuclear Proteins | 2 | 2021 | 749 | 0.230 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 369 | 0.220 |
Why?
| | Dendritic Cells | 2 | 2021 | 502 | 0.210 |
Why?
| | Cell Line, Tumor | 9 | 2024 | 3611 | 0.210 |
Why?
| | Antigens, Viral | 2 | 2021 | 179 | 0.200 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4522 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2195 | 0.200 |
Why?
| | Cell Proliferation | 6 | 2020 | 2542 | 0.200 |
Why?
| | Immunity, Cellular | 2 | 2019 | 267 | 0.190 |
Why?
| | Spleen | 2 | 2002 | 517 | 0.190 |
Why?
| | Lymphocyte Depletion | 2 | 2021 | 136 | 0.190 |
Why?
| | Humans | 35 | 2024 | 143560 | 0.190 |
Why?
| | Cell Separation | 2 | 2018 | 311 | 0.190 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2020 | 72 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 100 | 0.190 |
Why?
| | Peritoneal Cavity | 1 | 2002 | 30 | 0.190 |
Why?
| | Polycystic Kidney Diseases | 1 | 2023 | 73 | 0.190 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 118 | 0.190 |
Why?
| | Acute Lung Injury | 2 | 2017 | 300 | 0.180 |
Why?
| | Sequence Deletion | 1 | 2002 | 193 | 0.180 |
Why?
| | Lymphocytic choriomeningitis virus | 2 | 2018 | 33 | 0.180 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 974 | 0.170 |
Why?
| | Adaptive Immunity | 2 | 2023 | 170 | 0.170 |
Why?
| | Tryptophan | 1 | 2023 | 181 | 0.170 |
Why?
| | RNA Polymerase III | 1 | 2021 | 32 | 0.170 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2024 | 261 | 0.170 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1051 | 0.170 |
Why?
| | Immune Tolerance | 2 | 2020 | 381 | 0.170 |
Why?
| | Gamma Rays | 1 | 2020 | 57 | 0.160 |
Why?
| | Epithelial Cells | 3 | 2018 | 1125 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 111 | 0.160 |
Why?
| | Aldehyde-Lyases | 1 | 2020 | 3 | 0.160 |
Why?
| | Cells, Cultured | 5 | 2018 | 4182 | 0.160 |
Why?
| | Thymocytes | 1 | 2020 | 34 | 0.160 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.160 |
Why?
| | Sphingosine | 1 | 2020 | 47 | 0.150 |
Why?
| | Ileitis | 1 | 2020 | 33 | 0.150 |
Why?
| | Complement Factor H | 1 | 2020 | 79 | 0.150 |
Why?
| | Lysophospholipids | 1 | 2020 | 75 | 0.150 |
Why?
| | Discoidin Domain Receptor 2 | 1 | 2019 | 6 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.150 |
Why?
| | Ephrin-B2 | 1 | 2019 | 45 | 0.150 |
Why?
| | Cell Line | 7 | 2018 | 2897 | 0.150 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1263 | 0.150 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 2018 | 22 | 0.140 |
Why?
| | Dasatinib | 1 | 2019 | 59 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 391 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2018 | 499 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 30 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2019 | 273 | 0.140 |
Why?
| | Varicellovirus | 1 | 2018 | 17 | 0.140 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 174 | 0.140 |
Why?
| | Monkey Diseases | 1 | 2018 | 25 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 402 | 0.130 |
Why?
| | Receptors, Complement | 1 | 2017 | 121 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 443 | 0.130 |
Why?
| | Transplantation Tolerance | 1 | 2017 | 37 | 0.130 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 365 | 0.120 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2020 | 308 | 0.120 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2017 | 75 | 0.120 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 404 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 422 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 217 | 0.120 |
Why?
| | Chemokines, CXC | 1 | 2016 | 70 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 644 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 482 | 0.120 |
Why?
| | Blood Substitutes | 1 | 1996 | 28 | 0.120 |
Why?
| | Crohn Disease | 1 | 2020 | 256 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2019 | 222 | 0.120 |
Why?
| | Mice, 129 Strain | 2 | 2013 | 87 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 2097 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 214 | 0.120 |
Why?
| | Immune Evasion | 1 | 2016 | 64 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 647 | 0.120 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.120 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 70 | 0.120 |
Why?
| | Papillomaviridae | 1 | 2016 | 121 | 0.120 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 372 | 0.110 |
Why?
| | Rhadinovirus | 1 | 2015 | 20 | 0.110 |
Why?
| | Aminopeptidases | 2 | 2024 | 22 | 0.110 |
Why?
| | V(D)J Recombination | 1 | 2014 | 8 | 0.110 |
Why?
| | Complement Activation | 1 | 2017 | 412 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4241 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 167 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 994 | 0.110 |
Why?
| | Adenosine | 2 | 2013 | 251 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2020 | 764 | 0.100 |
Why?
| | Gene Expression | 1 | 2019 | 1505 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2020 | 758 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2023 | 1252 | 0.100 |
Why?
| | Mice, Inbred NOD | 1 | 2015 | 607 | 0.100 |
Why?
| | Perioperative Period | 1 | 2013 | 70 | 0.100 |
Why?
| | Hemoglobins | 1 | 1996 | 365 | 0.100 |
Why?
| | Graft Rejection | 1 | 2017 | 551 | 0.100 |
Why?
| | Virulence Factors | 1 | 2015 | 172 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 341 | 0.100 |
Why?
| | Lymphocytes, Null | 1 | 2012 | 3 | 0.100 |
Why?
| | Antigens | 2 | 2020 | 350 | 0.100 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2012 | 27 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 319 | 0.100 |
Why?
| | Thymoma | 1 | 2012 | 36 | 0.100 |
Why?
| | Nerve Growth Factors | 1 | 2013 | 79 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2024 | 941 | 0.100 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 47 | 0.100 |
Why?
| | Pneumonia, Viral | 1 | 2018 | 378 | 0.100 |
Why?
| | Computational Biology | 1 | 2018 | 677 | 0.100 |
Why?
| | Reperfusion | 1 | 2012 | 46 | 0.090 |
Why?
| | Aspirin | 1 | 1996 | 398 | 0.090 |
Why?
| | Jurkat Cells | 1 | 2012 | 118 | 0.090 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 2012 | 9 | 0.090 |
Why?
| | Lung | 3 | 2017 | 4101 | 0.090 |
Why?
| | Intraoperative Complications | 1 | 2013 | 155 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 20 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2020 | 924 | 0.090 |
Why?
| | Intestinal Diseases | 1 | 2012 | 42 | 0.090 |
Why?
| | Antigenic Variation | 1 | 2011 | 11 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2012 | 70 | 0.090 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 13 | 0.090 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1143 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1864 | 0.090 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2013 | 202 | 0.090 |
Why?
| | Cell Hypoxia | 1 | 2012 | 241 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 309 | 0.090 |
Why?
| | Vaccines, Subunit | 1 | 2011 | 52 | 0.090 |
Why?
| | Hospital Mortality | 1 | 2016 | 962 | 0.090 |
Why?
| | Perioperative Care | 1 | 2013 | 234 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 346 | 0.080 |
Why?
| | Nitric Oxide | 1 | 1996 | 899 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 698 | 0.080 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 98 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 330 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 474 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1794 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 911 | 0.080 |
Why?
| | Blotting, Western | 1 | 2013 | 1223 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2011 | 166 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1813 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1557 | 0.080 |
Why?
| | Purines | 1 | 2011 | 185 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 484 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 504 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 638 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 306 | 0.080 |
Why?
| | Colitis | 1 | 2012 | 281 | 0.080 |
Why?
| | Endothelium, Vascular | 1 | 1996 | 962 | 0.070 |
Why?
| | Female | 13 | 2020 | 77251 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2016 | 2020 | 0.070 |
Why?
| | Intestines | 1 | 2012 | 356 | 0.070 |
Why?
| | Integrin alpha4 | 1 | 2008 | 7 | 0.070 |
Why?
| | Interleukin-1 | 1 | 2012 | 970 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2023 | 617 | 0.070 |
Why?
| | Male | 11 | 2020 | 71500 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 863 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 710 | 0.070 |
Why?
| | Models, Immunological | 1 | 2008 | 101 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2011 | 325 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2021 | 1171 | 0.070 |
Why?
| | Gastric Mucosa | 1 | 2007 | 53 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2018 | 336 | 0.060 |
Why?
| | Phenotype | 2 | 2021 | 3211 | 0.060 |
Why?
| | Virulence | 2 | 2015 | 275 | 0.060 |
Why?
| | Salmonella enterica | 1 | 2007 | 57 | 0.060 |
Why?
| | Salmonella Infections | 1 | 2007 | 60 | 0.060 |
Why?
| | Health | 1 | 2007 | 83 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 763 | 0.060 |
Why?
| | Immunity | 1 | 2007 | 138 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1062 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2417 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 884 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 57 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1474 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 169 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 58 | 0.050 |
Why?
| | Viral Plaque Assay | 1 | 2002 | 34 | 0.050 |
Why?
| | Obesity | 1 | 2016 | 3041 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 69 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 133 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2002 | 157 | 0.050 |
Why?
| | Kynurenine | 1 | 2023 | 115 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 120 | 0.050 |
Why?
| | Cell Communication | 2 | 2017 | 313 | 0.050 |
Why?
| | Smoking | 1 | 2009 | 1580 | 0.040 |
Why?
| | Macrophages | 2 | 2019 | 1506 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 27 | 0.040 |
Why?
| | Luciferases | 1 | 2021 | 152 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2013 | 2887 | 0.040 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.040 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2020 | 24 | 0.040 |
Why?
| | Cetuximab | 1 | 2021 | 108 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2020 | 1511 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 233 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 944 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.040 |
Why?
| | Immunocompetence | 1 | 2000 | 47 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 92 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 53 | 0.040 |
Why?
| | Gene Targeting | 1 | 2000 | 82 | 0.040 |
Why?
| | Tumor Burden | 1 | 2021 | 319 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 38 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 87 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 438 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Mutation | 2 | 2023 | 4053 | 0.040 |
Why?
| | Interferons | 1 | 2021 | 195 | 0.040 |
Why?
| | Neoplasms | 2 | 2024 | 2804 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 30 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 317 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 823 | 0.040 |
Why?
| | Pyrimidines | 1 | 2023 | 524 | 0.040 |
Why?
| | Mice, SCID | 1 | 2000 | 372 | 0.040 |
Why?
| | Indoles | 1 | 2023 | 479 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 129 | 0.040 |
Why?
| | Transfection | 1 | 2021 | 949 | 0.040 |
Why?
| | Homeodomain Proteins | 2 | 2013 | 523 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 361 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 148 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2019 | 169 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 138 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 748 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 201 | 0.030 |
Why?
| | DNA Repair | 1 | 2020 | 250 | 0.030 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 81 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 25 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 38 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2021 | 438 | 0.030 |
Why?
| | Lymphocytes | 1 | 2020 | 398 | 0.030 |
Why?
| | Complement C3d | 1 | 2017 | 67 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 234 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 191 | 0.030 |
Why?
| | Radiotherapy | 1 | 2018 | 206 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 99 | 0.030 |
Why?
| | Cell Cycle | 1 | 2020 | 648 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 545 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1314 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2016 | 42 | 0.030 |
Why?
| | Arenaviridae Infections | 1 | 2016 | 17 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 190 | 0.030 |
Why?
| | Ovalbumin | 1 | 2017 | 197 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1332 | 0.030 |
Why?
| | Lectins, C-Type | 1 | 2016 | 62 | 0.030 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2016 | 11 | 0.030 |
Why?
| | Granzymes | 1 | 2016 | 50 | 0.030 |
Why?
| | Calcimycin | 1 | 1996 | 37 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 288 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 963 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1996 | 49 | 0.030 |
Why?
| | Cyclic GMP | 1 | 1996 | 91 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 431 | 0.030 |
Why?
| | Renal Artery | 1 | 1996 | 43 | 0.030 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 22 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 414 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 213 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 80 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2020 | 8072 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 223 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 79 | 0.030 |
Why?
| | Cell Survival | 1 | 2018 | 1136 | 0.030 |
Why?
| | Acetylcholine | 1 | 1996 | 204 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 1996 | 241 | 0.030 |
Why?
| | Cyclic AMP | 1 | 1996 | 215 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 59 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 861 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1736 | 0.030 |
Why?
| | Immunoblotting | 1 | 2015 | 313 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 22 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 427 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 14 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 28 | 0.030 |
Why?
| | Femoral Artery | 1 | 1996 | 188 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 59 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 41 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 62 | 0.030 |
Why?
| | Autoimmunity | 1 | 2020 | 927 | 0.030 |
Why?
| | California | 1 | 2016 | 467 | 0.030 |
Why?
| | DNA Primers | 1 | 2015 | 518 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2018 | 723 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1064 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 301 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2016 | 227 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 973 | 0.030 |
Why?
| | Netrin-1 | 1 | 2013 | 15 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 394 | 0.020 |
Why?
| | Imidazoles | 1 | 2014 | 252 | 0.020 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2012 | 29 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2016 | 272 | 0.020 |
Why?
| | Adenosine Deaminase | 1 | 2013 | 44 | 0.020 |
Why?
| | Vasodilation | 1 | 1996 | 515 | 0.020 |
Why?
| | Adult | 3 | 2023 | 40013 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 1996 | 839 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 219 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 8 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 29 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 30 | 0.020 |
Why?
| | Albuminuria | 1 | 2013 | 186 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1282 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 33 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2012 | 136 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4152 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 75 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2519 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 498 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 211 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2056 | 0.020 |
Why?
| | Antigens, CD | 1 | 2014 | 549 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 504 | 0.020 |
Why?
| | Receptors, Purinergic | 1 | 2011 | 18 | 0.020 |
Why?
| | DNA Methylation | 1 | 2016 | 667 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2856 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2011 | 184 | 0.020 |
Why?
| | Chemotaxis | 1 | 2011 | 122 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 1029 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1369 | 0.020 |
Why?
| | Alleles | 1 | 2012 | 893 | 0.020 |
Why?
| | Inflammasomes | 1 | 2011 | 146 | 0.020 |
Why?
| | Fibroblasts | 1 | 2015 | 1044 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 861 | 0.020 |
Why?
| | Immunoglobulin Class Switching | 1 | 2009 | 21 | 0.020 |
Why?
| | Phagocytosis | 1 | 2011 | 291 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3328 | 0.020 |
Why?
| | Aged | 2 | 2020 | 25322 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2011 | 510 | 0.020 |
Why?
| | Infection Control | 1 | 2009 | 173 | 0.020 |
Why?
| | Epitopes | 1 | 2009 | 489 | 0.020 |
Why?
| | Organ Specificity | 1 | 2007 | 311 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1072 | 0.020 |
Why?
| | Middle Aged | 2 | 2020 | 35342 | 0.010 |
Why?
| | Critical Illness | 1 | 2012 | 869 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1524 | 0.010 |
Why?
| | Stroke | 1 | 2013 | 1213 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1754 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 410 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 16741 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10644 | 0.010 |
Why?
| | Vaccination | 1 | 2009 | 1484 | 0.010 |
Why?
|
|
Clambey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|